| 3.73 -0.02 (-0.53%) | 08-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.55 |
1-year : | 5.32 |
| Resists | First : | 3.9 |
Second : | 4.55 |
| Pivot price | 2.89 |
|||
| Supports | First : | 2.8 |
Second : | 2.12 |
| MAs | MA(5) : | 3.36 |
MA(20) : | 2.75 |
| MA(100) : | 2.08 |
MA(250) : | 2.28 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 91.7  |
D(3) : | 91.6 |
| RSI | RSI(14): 71.3 |
|||
| 52-week | High : | 5.55 | Low : | 0.97 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PYXS ] has closed below upper band by 1.1%. Bollinger Bands are 100.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.75 - 3.77 | 3.77 - 3.79 |
| Low: | 3.09 - 3.11 | 3.11 - 3.12 |
| Close: | 3.72 - 3.75 | 3.75 - 3.78 |
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
Fri, 07 Aug 2026
Price to earnings forward of Pyxis Oncology, Inc. – NASDAQ:PYXS - TradingView
Tue, 04 Aug 2026
Pyxis Oncology (NASDAQ:PYXS) Raised to Strong-Buy at Wells Fargo & Company - MarketBeat
Sat, 25 Jul 2026
PYXS|Pyxis Oncology Inc|Price:3.090|Chg%:-0.070 - TradingKey
Fri, 24 Jul 2026
Pyxis Oncology Inc (PYXS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tue, 14 Jul 2026
Pyxis Oncology: The Market Might Have Already Ruled On Micvotabart Pelidotin - Seeking Alpha
Tue, 30 Jun 2026
Pyxis Oncology raises up to $114M to fund MICVO trial updates - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 63 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 13.6 (%) |
| Held by Institutions | 42.8 (%) |
| Shares Short | 3,250 (K) |
| Shares Short P.Month | 2,020 (K) |
| EPS | -1.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.5 |
| Profit Margin | 0 % |
| Operating Margin | -600.3 % |
| Return on Assets (ttm) | -52 % |
| Return on Equity (ttm) | -121.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.18 |
| Sales Per Share | 0.21 |
| EBITDA (p.s.) | -1.25 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -67 (M) |
| Levered Free Cash Flow | -34 (M) |
| PE Ratio | -2.87 |
| PEG Ratio | 0 |
| Price to Book value | 7.46 |
| Price to Sales | 17.05 |
| Price to Cash Flow | -3.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|